



July 30, 2026

Ref:- GH/2026-27/EXCH/36

The General Manager
Dept. of Corporate Services
BSE Limited,
P J Towers, Dalal Street,
Mumbai - 400 001

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Scrip Code: 543654

Symbol: MEDANTA

Sub: Investor Presentation

Dear Sir(s),

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copy of Investor Presentation for the first quarter ended June 30, 2026 Results.

Kindly take the above on record.


Thanking you,

Yours faithfully

For Global Health Limited

Rahul Ranjan
Company Secretary & Compliance Officer
M. No. A17035

Encl: a/a





GLOBAL HEALTH LIMITED

Dedicated to Life

Investor Presentation

Q1 FY2027

30th July, 2026



This presentation, apart from historical information, contains some "forward-looking statements" including those describing the Company's strategies, strategic direction, objectives, future prospects, estimates etc. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by these statements. These factors include, but are not limited to general market conditions, macro-economic, movements in currency exchange and interest rates, the ability to attract and retain high quality human resource, competitive pressures, technological developments, governmental and regulatory trends, legislative developments, and other key factors beyond the control of the Company.

These forward looking statements are based on information currently available to us, and we assume no obligation to revise these statements as circumstances change. The Company may alter, modify or otherwise change in any manner the content of Presentation/Press Release, without obligation to notify any person of such revision or changes.

Contents

01 Q1 FY2027 Performance Update

02 Project Update and Capex Plan

03 Medanta's Journey, Purpose and Model of Healthcare

04 Annexures

01

Q1 FY2027 Performance Update

Q1 FY2027 performance summary

Revenue Growth of 26% y-o-y and EBITDA ex Noida growth of 24% y-o-y; Growth led by patient volumes

Total Income¹

INR 13,262 million

Q1 FY26
10,513 million


26.2%

EBITDA³ and Margins

EBITDA² ex Noida

INR 3,201 million
Margin: 25.8%

Q1 FY26
2,584 million
Margin: 24.6%


23.9%

Reported EBITDA

INR 3,153 million
Margin: 23.8%

Q1 FY26
2,553 million
Margin: 24.3%


23.5%

Profit after Tax and Margins

INR 1,573 million
Margin: 11.9%

Q1 FY26
1,590 million
Margin: 15.1%


-1.1%

Occupied Bed Days

173,064

Q1 FY26
142,898


21.1%

ARPOB* | ARPP* (INR)

70,244 **201,891**


5.5%
Q1 FY26
66,584


nm
Q1 FY26
201,795

ALOS (days)

2.87

Q1 FY26
3.03


-5.2%

Patient Footfalls

60,214
In-patients


27.7%
Q1 FY26
47,150

1,100,928
Out-patients**


34.5%
Q1 FY26
818,815

1. Noida generated Total Income of INR 855 million

2. Noida EBITDA loss narrowed to INR 49 million in Q1 FY27 from INR 236 million in Q4 FY26. Q1 FY26 EBITDA loss stood at INR 30 million

3. EBITDA represents EBITDA before ESOP expenses

Q1 FY2027 performance summary

Revenue growth of 26% y-o-y, primarily led by increase in patient volumes and realization

- Highest ever quarterly total income of INR 13,262 million; growth of 26.2% y-o-y
- EBITDA¹ (ex-Noida) grew 23.9 % y-o-y to INR 3,201 with improved margins of 25.8% in Q1 FY27. EBITDA including Noida was INR 3,153 million, growth of 23.5% y-o-y and margins of 23.8%
- Noida hospital generated Total Income of INR 855 million and EBITDA loss of INR 49 million in Q1 FY27, compared to total income of INR 525 million and EBITDA loss of INR 236 million reported in Q4 FY26
- Profit After Tax was INR 1,573 million, compared to INR 1,590 million in Q1FY6. PAT margins were at 11.9% compared to 15.1% in Q1 FY26. To highlight, Q1FY26 had a non-recurring exceptional income of INR 196 million primarily due to reversal of potential interest liability on EPCG following transfer of EPCG license from MHPL to GHL
- During the quarter, total 72 new beds were added across the network; 21 beds were added at Lucknow and 51 beds in Noida
- Volume growth continues to remain robust, In-patient count increased by 27.7% while Out-patient count increased by 34.5% y-o-y
- Occupied bed days increased by 21.1% y-o-y, representing an occupancy of ~63% on increased bed capacity while excluding Noida, occupancy stood at 66%
- ARPOB stood at INR 70,224, up by 5.5% y-o-y, driven by improvement in ALOS (from 3.03 days in Q1FY26 to 2.87 days in Q1FY27) and change in case mix
- ARPP for the quarter was INR 201,891, compared to INR 201,795 in same quarter last year.
- During the quarter, International Patients Revenue increased by 23.0% y-o-y to INR 782 million
- OPD Pharmacy (Hospital & Retail) business continues to witness robust growth. Revenue increased by 50.9% y-o-y to INR 609 million in Q1 FY27

Q1 FY2027 clinical achievements

Continuing the legacy of clinical excellence

- A 45-year-old **critically ill lung adenocarcinoma patient with complete left lung collapse** and ventilator-dependent respiratory failure was successfully treated at Medanta Gurugram using **VV-ECMO-supported therapeutic bronchoscopy, tumour debulking** (electrocautery and cryotherapy) and **Y-stent placement**, restoring airway patency and re-expanding the collapsed lung
- Medanta Gurugram successfully treated **a rare case of DYT1 dystonia in a 12-year-old patient** using **Deep Brain Stimulation (DBS)**, restoring the patient's ability to walk
- A 61-year-old woman with a **rare and life-threatening paraesophageal hernia with gastric volvulus** underwent **robotic-assisted paraesophageal hernia repair with gastropexy** at Medanta Noida and was discharged within three days
- Medanta Lucknow crossed the milestone of **1,000 joint replacement surgeries using advanced robotic technology** within one year of launch of robotic orthopaedic and joint replacement program, reflecting the rapid scale-up of the robotic program
- **Medanta Lucknow** became the **first private healthcare institution in Uttar Pradesh** to **successfully performed a Whole Lung Lavage for a patient with Pulmonary Alveolar Proteinosis (PAP)**
- Doctors at **Medanta Patna** successfully performed the unit's **first Transarterial Chemoembolization procedure** for a patient with **hepatocellular carcinoma and decompensated chronic liver disease (Child-Pugh B8)**, marking a significant milestone in advanced liver cancer care.
- **A critically ill 10-month-old infant** suffering from **hepatoblastoma and acute kidney injury** was successfully treated at Medanta Patna using **Continuous Renal Replacement Therapy (CRRT)**. The case is likely the first in Bihar where a specialized bilirubin adsorption system was connected in series with a plasma filter, helping save the child's life

Q1 FY2027 Business Update

Strengthening the core and building strong pipeline for growth



Capacity Expansion

- ✓ **Noida:** 51 beds added on 9th Floor A-Wing
- ✓ **Lucknow:** 21 beds added on the 9th floor of Tower A
- ✓ **Ranchi:** Launched Surgical Oncology services
- ✓ **Indore Cancer Unit:** Addition of an 80-bed cancer hospital, announced in April 2026, to be operationalized in Q2/Q3 FY27. Equipment Procurement and on-boarding of clinicians on track.



Attract Best Talent

- ✓ **70+ Doctors on-boarded in** Q1 FY27 across Medanta network hospitals
- ✓ **50+ senior clinicians;** on-boarded during the quarter
- ✓ **Major on-boarding is across** key clinical departments such as Cardiac, Cancer, Neurosciences, Urology and Orthopaedics



New Medical Equipment Deployed in Q1 FY27



MISSO Ortho Robotic System - **Gurugram**



Stealth Station S8 - Surgical Navigation System **Lucknow**



J&J VELYS Orthopaedic Surgical Robot – **Lucknow & Patna**



Continuity of Care

- ✓ **825+ active touch points and 325+ collection centers** across 100+ cities supported by 12 labs and 4 HLMs /RLMs. Achieved 1.56 lakh patient bookings, a growth of 21% YoY
- ✓ **22 operational pharmacy** comprising of, 7 Pharmacies in the Hospital, 2 Mediclinics and 13 Retail Pharmacies

Medanta Noida: Scaling Operations and Strengthening Clinical Capabilities

Continued ramp-up in patient volumes, clinical programs, and specialty services

Medanta Noida Overview

550+ Planned beds capacity	433 Operational beds
250+ Experienced Doctors	40 Directors
80+ Senior clinicians	25+ Super Speciality
720+ Nurses and paramedics	1,400+ Full-time employees

Key metrics	30 Sep 2025	31 Dec 2025	31 Mar 2026	30 June 2026
Total Census Bed	141	231	274	323
Daycare Beds	85	97	108	110
Total Bed Capacity	226	328	382	433
No. of OT's	5	14	14	14


KEY UPDATES – Q1FY27

- LINAC and Brachytherapy operationalized
- 51 beds added in 9th Floor A-wing
- All major Insurance & PSU empanelment completed
- Performed 5,000+ procedures in Q1 FY27


Medanta Noida: Fully Operational with 433 beds

Noida operations gaining momentum, substantial reduction in EBITDA losses in Q1FY27

Total Income (INR million)



EBITDA¹ (INR million)




1. EBITDA represents EBITDA before ESOP Expenses


Key operating metrics: Revenue and profitability

Strong start to FY2027; Revenue growth of 26% with EBITDA growth (including Noida EBITDA loss) at 24%


Total Income (INR million)




Profit before tax² (INR million and margin%)



EBITDA¹ (INR million and margin %)



Profit after tax² (INR million and margin %)




1. EBITDA represents EBITDA before ESOP expenses

2. PBT and PAT growth impacted due to a non-recurring exceptional income of INR 196 million in Q1 FY26 primarily due to reversal of potential interest liability on EPCG following transfer of EPCG license from MHPL to GHL


Key operating metrics: Volumes, occupancies, ALOS

Growth driven by in-patient volume growth of 28% y-o-y; Occupancy at 63% on the increased bed capacity


Average census and occupied beds




ALOS (days)



IPD volumes ('000)




OPD volumes ('000)




Key operating metrics: ARPOB and revenue mix

ARPOB growth driven by improvement in ALOS and change in specialty mix


ARPOB¹ (INR)




ARPP¹ (INR)




IPD Revenue mix by payor category²



Domestic and International revenue mix



IPD vs OPD revenue breakdown




1. ARPOB calculated on Hospital Revenues excluding OPD Pharmacy and Other Income divided by Occupied bed days; ARPP calculated on Hospital Revenues excluding OPD Pharmacy and Other Income divided by Inpatient Volumes

2. IPD revenue mix by payor category is based on payment type

Diverse revenue¹ mix

Significant contribution from complex specialties




Notes:

1. Revenue from healthcare services excludes pharmacy revenue and other income
2. Revenue breakdowns are provided as per internal MIS at the Company's consolidated level
3. Cancer includes medical oncology, radiation oncology, head & neck surgery, bone marrow transplant and breast surgery


Cluster 1 hospitals - Gurugram, Indore and Ranchi

Consistent Growth with Improved Margins


Total Income (INR million)




EBITDA (INR million and margin %)




ARPP (INR)




In-patient Volume (count)




ALOS (days)



Occupied Bed Days (count)




ARPOB (INR)




Cluster 2 hospitals – Lucknow, Patna and Noida

Strong Revenue and EBITDA Growth Continues


Total Income (INR million)




EBITDA (INR million and margin %)




ARPP (INR)




In-patient Volume (count)




ALOS (days)



Occupied Bed Days (count)



ARPOB (INR)




04

Project Update and Capex Plan

On-going expansion projects

~20% Capacity added in FY26. Planned bed capacity addition to drive sustainable growth


Number of installed beds



- ❖ **Noida with total capacity of 550 beds:** 51 beds added in Q1 FY27, taking total bed count to 433 beds at the end of June 2026
- ❖ **Lucknow:** 21 Beds added 9th floor A wing during the quarter taking total bed count of 778 beds.
- ❖ **South Delhi:** Announced 400 bed in partnership with DLF. Construction is in progress on site 1
- ❖ **Pitampura, New Delhi:** Signed O&M Agreement to jointly build and operate and manage a ~750 bed hospital. Building plan under preparation
- ❖ **Mumbai:** Land acquired in October 2024. Additional FSI and Chief Fire Officer approval received. MHADA and Environmental Clearance awaited.
- ❖ **Guwahati, Assam:** Land acquisition and possession completed. Following a revision in National Building Code (NBC) norms, bed capacity has been increased from 400 to 650.
- ❖ **Varanasi:** 400-bed project announced in March 2026 under built to suit and lease arrangement with developer. Building plans under preparation.
- ❖ **Indore Cancer Unit:** Addition of an 80-bed cancer hospital under business transfer agreement, announced in April 2026, to be operationalized in Q2/Q3 FY27

Capex plan next 5 years

Total capex of ~INR 48,500 million planned for next 5 years



- In Q1 FY2027, Rs. 1,610 million of capex has been incurred
- Guwahati Project: Due to scale up of Guwahati project to 650 beds, the total capex for the hospital would be INR 9,700 million
- Maintenance capex estimated at INR ~6,000 million to be incurred over next three years
- Total capex estimated at INR ~48,500 million, to be funded by combination of Debt funding and internal accruals

05

Medanta's Journey, Purpose and Model of Healthcare

Medanta was founded to bring a new type of healthcare to India...

... the human side of healthcare

Healthcare is never only about science. It is also about the **art of medicine** – the **human connection**, putting the **patient first**, **collaboration**, the personal acts of **empathy** and the **values** that guide our decision making.



At Medanta we have built an institution to match the highest benchmarks of excellence globally. We have created an ecosystem of excellence that encompasses world-leading clinicians, state-of-the-art equipment, best-in-class infrastructure, and a strong emphasis on research and innovation.


Medanta's patient-first approach allows teams of super-specialist doctors to collaborate seamlessly and arrive at the best-possible treatment customized for each patient in line with our guiding philosophy 'Har Ek Jaan Anmol', meaning 'Every Life is Invaluable'



Dr. Naresh Trehan
CMD & Chief Cardiac Surgeon, Medanta

Growth from a single flagship hospital in Gurgaon...

...to a network of 6 high quality hospitals across north India



*Carlyle Group (Anant Investments) exited completely in the IPO

From our flagship Medicity campus in Gurgaon, we have grown to 3,737 beds across 6 cities

Largest private hospital beds in operation under one roof in Delhi (NCR), Uttar Pradesh and Bihar



Gurgaon

1,440 beds; 316 ICU beds



LUCKNOW

778 beds; 211 ICU beds (950 planned)



PATNA

601 beds; 176 ICU beds (650 planned)



INDORE

175 beds; 53 ICU beds



RANCHI

310 beds; 102 ICU beds




NOIDA

433 beds; 98 ICU beds (550 planned)

One of the largest private hospital chains in North and East India

Serving over 400 million people in the States with Medanta facilities



Our Network

Hospital Network

6 Multi-speciality hospitals
5 Upcoming hospitals

Bed Capacity

3,737 Total Beds
3,350+ Planned Bed Addition

Infrastructure

950+ ICU Beds
100+ Operating Theatres

Continuity of care

Medanta Clinics

9 Clinics
6 cities

Medanta Labs

12 Labs total
825+ Collection centre

Pharmacy

22 Pharmacy
10+ Planned

Our People

Doctors

2,480

Nurses and paramedics

8,180+

Full-time and retainer employees

14,325

Embracing a new era and redefining our purpose

MISSION

Our mission is to deliver world class, patient centric, integrated and affordable healthcare through a dynamic institution that focuses on the development of people and knowledge

Core Values



Patient centric care: Foster a culture where every one of us is committed to care for patients and their caregivers



Leadership and quality: Commit to delivering excellence in everything we do through exemplary action and behaviour




Integrity and courage: Maintain the highest ethical standards by putting the patient first and demonstrating the courage to do what is right



Collaboration, learning and innovation: Promote teamwork and collaboration, welcome change and creativity, encourage innovation

The Medanta Model of Healthcare

Delivering the highest quality of medicine with care and compassion




What it means for patients and caregivers?

- Super specialized doctors provide the highest quality of care through a team based integrated approach
- A safe and friendly healing environment with a patient-centric design in all clinical areas and public spaces
- Availability of the most advanced, innovative equipment and technology to enable the most complex diagnostics and treatment
- Doctors who take ownership and personal responsibility
- Respect-based processes for patients and their families

Medanta is well placed to deliver sustainable growth...

...while maintaining its core values of patient centric care and clinical leadership and quality



06

Annexures

Annexure: Profit and Loss Statement

INR million	Quarter			Y-o-Y Growth %	Q-o-Q Growth %
	Q1FY2026	Q4FY2026	Q1FY2027		
Revenue from operations	10,308	11,590	13,041	26.5%	12.5%
Other income	205	367	222	8.3%	(39.7)%
Total income	10,513	11,958	13,262	26.2%	10.9%
Cost of materials consumed	2,391	2,465	2,944	23.1%	19.4%
Employee benefits expense	3,852	4,615	5,136	33.3%	11.3%
Other expenses	1,717	1,971	2,029	18.2%	2.9%
EBITDA	2,553	2,906	3,153	23.5%	8.5%
EBITDA Margins %	24.3%	24.3%	23.8%	(51) bps	(53) bps
ESOP Expenses	79	101	64	(18.8)%	(36.6)%
EBITDA after ESOP expenses	2,474	2,805	3,089	24.8%	10.1%
Finance costs	138	267	267	93.5%	(0.1)%
Depreciation and amortisation expense	451	665	690	52.9%	3.7%
Exceptional item ¹	(196)	0	0	(100.0)%	NA
Profit before tax	2,081	1,873	2,133	2.5%	13.9%
Tax expenses	492	456	560	13.9%	22.8%
Profit after tax	1,590	1,417	1,573	(1.1)%	11.0%

1. Q1FY26 had a non-recurring exceptional income of INR 196 million primarily due to reversal of potential interest liability on EPCG following transfer of EPCG license from MHPL to GHIL

Annexure: Operational Parameters

Key metrics	Quarter			Y-o-Y Growth %
	Q1 FY26	Q4 FY26	Q1 FY27	
Total Beds	3,062	3,665	3,737	22.0%
Census Beds	2,487	2,950	3,037	22.1%
Occupied Bed Days	142,898	1,61,429	1,73,064	21.1%
Occupancy Rate %	63.2%	60.9%	62.6%	(53) bps
ARPOB (INR) ¹	66,584	66,687	70,244	5.5%
ARPP (INR) ²	201,795	204,034	201,891	0.0%
ALOS (days)	3.03	3.06	2.87	(5.2)%
In-Patient Volumes	47,150	52,762	60,214	27.7%
Out-Patient Volumes	818,815	9,15,420	11,00,928	34.5%

- ¹ARPOB is calculated on Hospital Revenues excluding OPD Pharmacy and Other Income divided by Occupied bed days
- ²ARPP is calculated on Hospital Revenues excluding OPD Pharmacy and Other Income divided by Inpatient Volumes
- Census Beds as based on monthly average during the period
- Out-Patient volumes are sum of encounters at Out-Patient departments

Abbreviations

- INR : Indian Rupee
- NABH : National Accreditation Board for Hospitals & Healthcare Providers
- NABL : National Accreditation Board for Testing and Calibration Laboratories
- JCI : Joint Commission International
- OPD : Out-Patient Department
- IPD : In Patient Department
- ICU : Intensive Care Unit
- Mn : Million
- ARPOB : Average Revenue Per Occupied Bed
- ARPP: Average Revenue per Inpatient
- ALOS : Average Length of Stay
- EBITDA: EBITDA represents Profit before tax after adding back finance costs, ESOP expenses and depreciation and amortization of the relevant year/period
- EBITDA Margin : EBITDA divided by Total Income in percentage
- PAT : Profit After Tax
- NCR : National Capital Region

Definitions

- Bed Capacity / Installed Beds : Total Bed available in the hospital (including census (bed available for mid-night occupancy) and non-census beds (all other bed available other than census beds, i.e., day-care beds).
- Occupied beds : Total Count of patients at midnight at each day
- Average Occupancy Levels : (Total Occupied beds/Total census beds) i.e. Excluding day Care bed, Emergency, Dialysis beds, Pre & post catherization & Observation room
- ICU Beds: No of ICU Beds available in the hospital out of census beds
- Total Income : Revenue from Operations + Other Income
- ARPOB : Income from Health Care Services excluding OPD Pharmacy and Other Income revenue divided by occupied bed days
- ARPP : Income from Health Care Services excluding OPD Pharmacy and Other Income revenue divided by Inpatient Volume
- ALOS : Average number of days spent by admitted inpatients
- Revenue mix by Payment Type, i.e. Cash, TPA,CGHS, ECHS, PSU others.

About Medanta

Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon who has been awarded the prestigious Padma Bhushan and the Padma Shri, the third- and fourth-highest civilian awards in India, and the Dr. B.C. Roy Award in recognition of his distinguished contribution to medicine.

Global Health Limited (the "Company") is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, with key specialties cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology, according to the report titled "An assessment of the healthcare delivery market in India, September 2022" by CRISIL Limited.

Under the "Medanta" brand, the Company has a network of six hospitals currently in operation (Gurgaon, Indore, Ranchi, Lucknow, Patna and Noida). Spanning an area of 5.6 million sq. ft., its operational hospitals have 3,737 installed beds as on June 30, 2026. The Company provides healthcare services in over 30 medical specialties and engages over 2,480 doctors led by highly experienced department heads.

Contact Details

Gaurav Chugh
Head Investor Relations



+91 99585 88900



Gaurav.Chugh@Medanta.org



Corporate Office

Medanta; The Medicity

CH Baktawar Singh Rd, Medicity, Islampur Colony, Sector 38,
Gurgaon, Haryana 122001



For further information, please visit our website:

<https://www.medanta.org/>

Bhushan Khandelwal
Investor Relations



+91 7588844495

Bhushan.Khandelwal@Medanta.org